126 related articles for article (PubMed ID: 38031642)
21. Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents.
Li Z; Luo M; Cai B; Haroon-Ur-Rashid ; Huang M; Jiang J; Wang L; Wu L
Eur J Med Chem; 2018 Sep; 157():665-682. PubMed ID: 30125725
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
24. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
26. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
Wang ZX; Wang S; Qiao XP; Li WB; Shi JT; Wang YR; Chen SW
Bioorg Med Chem; 2022 Nov; 74():117067. PubMed ID: 36272186
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors.
Zhou H; Qi Z; Liu D; Xue X; Wang C
Chembiochem; 2023 Sep; 24(18):e202300238. PubMed ID: 37366008
[TBL] [Abstract][Full Text] [Related]
30. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
[TBL] [Abstract][Full Text] [Related]
31. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
32. Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Librizzi M; Spencer J; Luparello C
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483253
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Wang J; Su M; Li T; Gao A; Yang W; Sheng L; Zang Y; Li J; Liu H
Eur J Med Chem; 2017 Mar; 128():293-299. PubMed ID: 28213282
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3-d]pyrimidine and Pyrrolo[2,3-b]pyridine Scaffolds.
Mao ND; Gao Y; Dang XW; Duan JL; Hui Z; Che H; Xu Y; Zhang H; He X; Garrido C; Ye XY
ChemMedChem; 2023 Jul; 18(14):e202200683. PubMed ID: 37126396
[TBL] [Abstract][Full Text] [Related]
35. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
36. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer potential of sophoridine and its derivatives: Recent progress and future perspectives.
Ur Rashid H; Rasool S; Ali Y; Khan K; Martines MAU
Bioorg Chem; 2020 Jun; 99():103863. PubMed ID: 32334197
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
39. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
40. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
